Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA) | ||
By: Nasdaq / GlobeNewswire - 23 Jun 2018 | Back to overview list |
|
Press Release - No. 17/2018 Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
Copenhagen, June 23, 2018 - Zealand Pharma ("Zealand") announces today that results from two studies on dasiglucagon will be presented at the 78th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Florida, in the U.S. held June 22-26 2018. Abstract No.'s 1230-P, and 102-OR will be presented today, Saturday June 23rd 2018. Dasiglucagon has the potential to create a paradigm shift in the treatment of people with insulin dependent diabetes using an automated artificial pancreas system. Dasiglucagon is a novel analog of glucagon that is stable in an aqueous formulation at body temperature and thus requires no reconstitution. The research results will be presented as an oral presentation and a poster at the ADA's Scientific Sessions:
On saturday June 23rd 11:30 AM Dr. Castle will present results from a non-clinical study assessing 6 and 9 months exposure of dasiglucagon in rats and dogs respectively. The data shows that chronic administration of dasiglucagon is well tolerated at levels exceeding human exposure. Results of this non-clinical study support continued investigation into long-term use of dasiglucagon in dual-hormonal artificial pancreas systems. "Automated management of type 1 diabetes using a dual-hormone artificial pancreas system requires insulin and glucagon. The data presented today for the first time demonstrates long-term safety and tolerability of the stable glucagon analog dasiglucagon. Together with the evidence that low doses of dasiglucagon effectively counteract low blood glucose, I believe these results bring us significantly closer to a potential paradigm shift in management of type 1 diabetes" says Jessica Castle, MD, Associate Professor, Harold Schnitzer Diabetes Health Center at the Oregon Health & Science University in Portland, OR, U.S. "Dasiglucagon is a potential first-in-class glucagon analog and a promising candidate for use in a dual-hormone artificial pancreas system for automated diabetes management. We look forward to continuing the next phase of our clinical development program to ultimately transform everyday life of people with type 1 diabetes." says Dr. Adam Steensberg, MD, Executive Vice President and Chief Medical and Development Officer of Zealand Pharma. For further information, please contact: Britt Meelby Jensen, President and CEO About Zealand Pharma A/S Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma. About dasiglucagon in dual-hormone pump therapy for diabetes Attachment |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |